UK FSA issues third batch of cultivated meat guidance

The UK Food Standards Agency has released its third set of support documents since December, continuing the cultivated meat sandbox programme that runs until February 2027. The FSA, in collaboration with Food Standards Scotland, has now issued eight such guidance documents through this initiative.

Dr Thomas Vincent, Deputy Director of Innovation at the FSA, stated that each batch of guidance makes the path to market authorisation clearer and more predictable for companies. The two-year effort has been funded by the Department of Science and Technology.

Guidance covers regulatory pathway and growth media safety

The new documents provide detailed scientific direction on assessing safety hazards linked to growth media components and lay out the approval framework for bringing products to market. One document focuses on growth media, setting out scientific guidance for assessing potential safety hazards associated with components used in growth media.

The regulatory authorisation guidance explains how the regulated products framework applies to cell-cultivated products and provides advice on handling changes after authorisation. For cultivated meat products that have already been approved, any changes in the manufacturing process that deviate from the terms of authorisation would require companies to submit a new application.

Sandbox programme structure and timeline

The Sandbox Programme launched in February 2025 and is due to run until February 2027. It is a controlled environment where businesses and researchers work with the FSA and FSS to design standards and guidance for new cultivated meat products.

The first two pieces of guidance, released in December, covered hygiene requirements, hazard analysis, and the scientific basis for evaluating the allergenicity and nutritional credentials of these products. The next tranche entailed four publications, spanning hygiene regulations; identity, production and microbiology; practical recommendations to prepare stronger, more complete filing; and supplementary information on novel food taste trials.

Industry impact and regulatory uncertainty

An upcoming Sanitary and Phytosanitary (SPS) deal between the UK and the EU may affect cultivated meat authorisations. The FSA has reportedly warned around 600 approval holders and businesses that the deal could render UK authorisations void. The deal could force companies to go through the EU's notoriously long and complex novel food process to sell their products in the UK.

The FSA, in its new guidance, confirmed that the SPS deal will affect its role in novel food approvals. It noted that the regulated products framework in Great Britain is the same as the one used in the EU.

This uncertainty has impacted business plans. Czech firm BeneMeat, which will roll out cultivated pet food in partnership with Forza10 in the EU this year, has paused its plans in the UK. The company said further progress is on hold as it and its prospective partners wait for clarity on whether Britain will retain the ability to develop its own regulatory pathway for biotechnologies. BeneMeat had invested in the UK, built local relationships, prepared controlled tastings, entered manufacturing talks, and filed a regulatory dossier to sell its cultivated meat for human food.

So far, only London-based Meatly has been cleared to sell cultivated meat in the UK, and that is for pet food. Several companies have applied for human food approval, including Aleph Farms, Ivy Farm Technologies, Mosa Meat, BeneMeat, and Parima's Gourmey and Vital Meat. Gourmey and Vital Meat are the furthest ahead in the process.

Pathway for approved products and future applicants

The FSA outlines a six-step process for novel food authorisation, from validation and risk assessment to public consultation and ministerial approval. The length of the process depends on how much information is provided, and how detailed it is.

The FSA has published research examining scientific issues relevant to the safety assessment of cell-cultivated products, including a review of analytical methods and research on genetic drift. This research is intended to help businesses consider what scientific evidence should be included in their applications.

According to one report, the FSA is hoping to complete safety evaluations of two cultivated meat products by the time the sandbox ends. The regulator has previously stated there is no fixed timeline for this.

Businesses can access all Sandbox guidance through the FSA’s Innovative Foods Guidance Hub. Companies developing cell-cultivated products can also request support with their market authorisation applications through the Sandbox Business Support Service. The FSA will hold a webinar on human safety assessment for novel foods on 8 October 2026 at 3pm BST.